| Date | Title | Description |
| 08.12.2025 | China Adds 114 Drugs to National Medical Insurance Catalog | (Yicai) Dec. 8 -- China has included 114 new drugs in the national basic medical insurance, maternity insurance, and work-related injury insurance drug list, focusing on filling gaps in major, rare, and chronic disease treatments.
New drugs... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 14.01.2022 | Coherus BioSciences : and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody - Form 8-K | Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include
TIGIT-Targeted Antibody
• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types
• Combin... |
| 10.01.2022 | Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody | • Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination
in clinical trials in multiple tumor types
• Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization
to new tumo... |
| 05.01.2022 | Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module | SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biociences Co., Ltd (“Junshi Biosciences”, HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, developm... |
| 13.12.2021 | Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment... | SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced posit... |
| 30.11.2021 | Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recur... | SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supp... |
| 15.11.2021 | Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer | REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that t... |
| 15.11.2021 | Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer | SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that t... |
| 01.11.2021 | Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma | FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877;... |
| 01.11.2021 | Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma | FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi ... |
| 15.09.2021 | Coherus BioSciences : and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine | REDWOOD CITY, Calif., and SHANGHAI, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced publi... |
| 15.09.2021 | Shanghai Junshi Biosciences : Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine | SHANGHAI and REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced publication o... |
| 14.09.2021 | Coherus BioSciences : Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences' Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conf... | REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation toda... |
| 01.09.2021 | Shanghai Junshi Biosciences : Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma | SHANGHAI, China and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the c... |
| 01.09.2021 | Coherus BioSciences : and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma | SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the ... |
| 31.08.2021 | Shanghai Junshi Biosciences : Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates | SHANGHAI, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announ... |
| 27.08.2021 | Shanghai Junshi Biosciences : Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody | SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announ... |
| 12.08.2021 | Coherus BioSciences : Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma | SHANGHAI, China and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that th... |
| 28.06.2021 | Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 | SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announc... |
| 29.04.2021 | SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Shanghai Junshi Biosciences : Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Se... | - Toripalimab data will also be featured in ASCO’s official press program -
SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) ... |
| 20.04.2021 | COHERUS BIOSCIENCES, INC.
Coherus BioSciences : Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences | REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 sto... |
| 30.03.2021 | SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Shanghai Junshi Biosciences : NOTICE OF THE 2020 ANNUAL GENERAL MEETING | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 30.03.2021 | Shanghai Junshi Biosciences : NOTICE OF THE 2020 ANNUAL GENERAL MEETING | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 26.02.2021 | SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Shanghai Junshi Biosciences : INSIDE INFORMATION - 2020 PRELIMINARY RESULTS ANNOUNCEMENT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 26.02.2021 | Shanghai Junshi Biosciences : INSIDE INFORMATION - 2020 PRELIMINARY RESULTS ANNOUNCEMENT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 01.12.2020 | Chinese edtech startup EEO Education gains US$ 265M in Series C funding | EEO Education was founded in 2014 and launched its first online classroom software, ClassIn, in 2015. The software initially targeted after-school education companies such as New Oriental and TAL Education. But its software is now being use... |
| 08.05.2020 | The Indianapolis-Shanghai partnership that could develop an effective COVID-19 remedy | |
